microRNA-152 Mediates DNMT1-Regulated DNA Methylation in the Estrogen Receptor α Gene

Yung-Song Wang1, Wen-Wen Chou1, Ku-Chung Chen1, Hsin-Yun Cheng1, Ruey-Tay Lin2,3,5, Suh-Hang Hank Juo1,4,5

1 Department of Medical Genetics, Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Department of Neurology, Kaohsiung Medical University, Kaohsiung, Taiwan, 3 Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 4 Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5 Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Abstract

Background: Estrogen receptor α (ERα) has been shown to protect against atherosclerosis. Methylation of the ERα gene can reduce ERα expression leading to a higher risk for cardiovascular disease. Recently, microRNAs have been found to regulate DNA methyltransferases (DNMTs) and thus control methylation status in several genes. We first searched for microRNAs involved in DNMT-associated DNA methylation in the ERα gene. We also tested whether statin and a traditional Chinese medicine (San-Huang-Xie-Xin-Tang, SHXXT) could exert a therapeutic effect on microRNA, DNMT and ERα methylation.

Methodology/Principal Findings: The ERα expression was decreased and ERα methylation was increased in LPS-treated human aortic smooth muscle cells (HASMCs) and the aorta from rats under a high-fat diet. microRNA-152 was found to be down regulated in the LPS-treated HASMCs. We validated that microRNA-152 can knock down DNMT1 in HASMCs leading to hypermethylation of the ERα gene. Statin had no effect on microRNA-152, DNMT1 or ERα expression. On the contrary, SHXXT could restore microRNA-152, decrease DNMT1 and increase ERα expression in both cellular and animal studies.

Conclusions/Significance: The present study showed that microRNA-152 decreases under the pro-atherosclerotic conditions. The reduced microRNA-152 can lose an inhibitory effect on DNA methyltransferase, which leads to hypermethylation of the ERα gene and a decrease of ERα level. Although statin can not reverse these cascade proatherosclerotic changes, the SHXXT shows a promising effect to inhibit this unwanted signaling pathway.

Introduction

Atherosclerosis is the major pathogenesis of cardiovascular disease that causes morbidity and mortality in industrialized countries [1]. This progressive multi-factorial process involves cellular signaling pathways [2–4], inflammatory mediators, growth factors, and adhesion molecules [5, 6]. Risk factors such as unhealthy dietary habits, aging and smoking contribute to the development of cardiovascular disease through increasing blood lipid levels and inflammation in the arterial wall. Eventually, arterial smooth muscle cells migrate and proliferate leading to atherosclerotic plaque formation and atherosclerosis development [7], [8]. Recently, DNA methylation has been implicated as a novel risk factor for atherosclerosis [9], [10].

DNA methylation is an important epigenetic modification on chromosomes that plays a significant role in the regulation of gene transcription [11]. When the cytosine and guanine contents are greater than 50% in the DNA sequence of humans, the high CG content regions can be hypermethylated causing transcriptional silencing [12]. Increasing evidence shows that global DNA hypomethylation is associated with gene transcriptional activity in the pathogenesis of cardiovascular diseases, including atherosclerosis [13–16]. Hiltunen et al. reported global DNA hypomethylation in the proliferating vascular smooth muscle cells (VSMCs) of human atherosclerotic plaque [9].

Estrogen receptor α (ERα) has been reported to protect against atherosclerosis and aging in the cardiovascular system [17], [18]. Increased expression of the ERα gene can reduce the proliferation of VSMCs [19], [20]. DNA methylation in the promoter region of the ERα gene can reduce transcription of ERα leading to a higher risk for several cardiovascular diseases [18].

It is known that DNA methylation is catalyzed by DNA methyltransferases (DNMTs), namely DNMT1, DNMT3α and DNMT3β. Methyltransferases use a reactive methyl group bound to sulfur in S-adenosyl methionine as the methyl donor. DNMT1 is the most abundant DNA methyltransferase in mammalian cells and the key maintenance enzyme for hemimethylated DNA during DNA replication of various cancer cells [21]. DNMT3α and DNMT3β are responsible for establishing de novo methylation and both enzymes...
exist in diverse cancer cells and cell lines [12], [22]. Both recent evidence and our previous study showed that microRNAs (miRs), which are noncoding RNAs, can be involved in the promoter methylation of CpG islands by targeting DNMTs 3’UTR [23–27]. Thus, we first aimed to search for miRNAs involved in DNMT-associated DNA methylation in the ERα gene.

Statin is a widely used lipid-lowering drug with multiple effects on the cardiovascular system [28]. Statin has been shown to have multiple mechanisms to reduce the cardiovascular risk including the anti-inflammation effects [29] and the inhibition of neointimal proliferation [30], [31]. We previously also found San-Huang-Xie-Xin-Tang (SHXXT), a traditional Chinese medicine, has several beneficial anti-atherosclerotic and anti-inflammatory effects [32]. In the present study, we also tested whether statin and SHXXT can regulate DNA methylation in the ERα gene as our second aim.

Results

ERα expression in LPS-treated HASMCs and HF feeding in rats

In our previous study, LPS (100 mg/ml) significantly induced the cell proliferation, migration and inflammation. In this study, we first found that LPS treatment significantly decreased ERα mRNA level and protein level at 48 h and 72 h (Fig. 1A and 1B). Furthermore, ERα expression can also be restored by SHXXT in a dose-dependent manner (Fig. 1A and 1B). However, simvastatin (1 μM) treatment had no effect on the decreased ERα at 48 h or 72 h (Fig. 1C). In order to confirm that the SHXXT effect on increasing ERα expression, we compared the mRNA and protein expression of the ERα gene in the aorta between the HF diet-fed SD rats with and without treatment of SHXXT. After 12 weeks, the ERα mRNA and protein levels were decreased in the HF diet-fed group as compared with the normal diet group (Fig. 2A and 2B).

DNMT1 expression in LPS-treated HASMCs

For the global methylation pattern, we found that the proportion of methylation in the Alu elements maintained at ~16% in HASMCs (measured at 48 h and 72 h) prior to LPS treatment. The proportion of methylation was substantially decreased to 5% at 72 h, although it was only decreased from 16% to 13% at 48 h after LPS treatment.

Since DNMT1 is the major enzyme for DNA methylation in mammals, we focused on this DNMT and tried to elucidate the
regulation mechanism. As shown in Fig. 3A and 3B, the increases of DNMT1 mRNA expression and protein levels in HASMCs were found at 48 h and 72 h after the treatment of LPS. When adding SHXXT (dose between 0.2 to 0.6 mg/ml), the mRNA and protein expression of DNMT1 were substantially reduced after incubation for 48 h and 72 h. On the contrary, neither mRNA nor protein level changed by treating simvastatin (Fig. 3C), which suggests simvastatin does not influence DNMT1-associated DNA methylation. Similar to the results from the cellular studies, DNMT1 expression in the aorta of SD rats was significantly increased in the HF-diet group and decreased by SHXXT (Fig. 3D and 3E). Therefore, we demonstrated a consistent change between ERα and DNMT1, and found a potential therapeutic effect of SHXXT.

Gain of ERα by DNMT1 knockdown

To further confirm that DNMT1 can influence ERα expression, we used shRNA to knock down the DNMT1 gene. The RNA interference caused a decrease of DNMT1 mRNA expression and protein expression by 57.3% and 58.2% respectively (Fig. 4A and 4B). When DNMT1 was inhibited, the mRNA and protein levels of ERα were simultaneously increased by 4.33- and 2.32-fold, respectively (Fig. 4A and 4B). These results clearly show that ERα can be silenced by DNMT1.

ERα methylation in LPS-treated HASMCs and HF fed rats

To determine if ERα locus undergoes promoter hypermethylation in LPS-treated HASMCs, we checked the methylation status of the CpG island located in the first exon of ERα gene (Fig. 5A) by the bisulfite specific PCR and sequencing (BSP) as well as methylation-specific PCR (MSP). We first measured the methylation degree of 24 CpG sites in exon 1 (nucleotides 146–354) by the BSP assay [33]. At 48 h and 72 h after LPS treatment, the methylation percentage was increased (57% and 77%, respectively) as compared with the control group (40% and 49%, respectively; Fig. 5B) in overall 24 CpG sites. Although we also found that the DNA methylation status of ERα can be reversed by SHXXT treatment, the drug effect mainly occurred at 72 h (55%). In the MSP assay, we found that DNA methylation status in the ERα exon 1 was also increased by LPS, and SHXXT partially reversed LPS-induced DNA hypermethylation at 48 h and 72 h (Fig. 5C). These data suggested that ERα exon 1 hypermethylation does occur in LPS-induced HASMCs and affect ERα expression. In order to confirm that the SHXXT effect on reducing ERα hypermethylation, we compared the methylation status of the ERα gene in of the aorta between the HF diet-fed SD rats with and without treatment of SHXXT. After 12 weeks, SHXXT could significantly reverse HF diet-induced DNA hypermethylation of the ERα gene (Fig. 5D).

miR-152 expression in LPS-treated HASMCs

To identify the atherosclerosis-related miRNAs, we used the miRNA arrays (OneArray microRNA expression profiling microarrays based on the latest miRBase release-version 17; Phalanx Biotech Group, Taiwan) to survey the miRNA expression levels between HASMCs treated and untreated with LPS (100 ng/mL). This commercial array used spotted probes to interrogate 1,087 human miRNAs. Among 1,087 surveyed miRNAs, the expression level of miR-152 was decreased by 2.3-fold when HASMCs were treated with LPS for 24 h (data not shown). Subsequent real-time PCR experiment confirmed that LPS can decrease miR-152 expression at 48 h and 72 h (P=0.0015 and 0.006; Fig. 6A).
Previous studies on cancers [23], [24] reported that miR-152 can bind to the 3’ untranslated region (UTR) of DNMT1. Accordingly, we speculated that miR-152 may be involved in DNMT1-associated DNA methylation in the cardiovascular system. Furthermore, our cellular studies showed that miR-152 levels can be induced by SHXXT in a dose-dependent manner, but cannot be induced by simvastatin for 48 h or 72 h (Fig. 6B). In the aorta of the SD rats, we confirmed that the miR-152 expression was down-regulated in the HF-diet group, and it can be up-regulated after 12-week treatment of SHXXT (n = 6; Fig. 6C).

**Gain and loss functions of ERα by miR-152**

To prove that miR-152 can regulate ERα gene expression via the suppression of DNMT1, we transfected the miR-152 precursor or inhibitor into the LPS-treated HASMCs. The results showed that the DNMT1 protein levels were reduced and consequently ERα protein levels were up-regulated by miR-152 precursor at 72 h (100 nM; Fig. 7A). On the contrary, DNMT1 protein levels were increased and consequently ERα protein levels were down-regulated by miR-152 inhibitor at 72 h (100 nM). These findings indicate that miR-152 indirectly up-regulated ERα expression through its binding to DNMT1. MSP analysis also showed that DNA methylation at ERα was reduced by miR-152 precursor in the LPS-treated cells (Fig. 7B). However, DNA methylation at ERα was increased by miR-152 inhibitor. Therefore, we demonstrated a consistent change between DNMT1 and ERα methylation by the change of miR-152 levels.

![Figure 3.](image-url)
The effect of miR-152 on HASMC proliferation and migration

To further examine whether miR-152 influences HASMC phenotypes through the change of ERα expression, the cell proliferation and migration were assessed at 48 h and 72 h after transfecting miR-152 precursor or inhibitor into the cells. The results demonstrated that the transfected miR-152 precursor resulted in a concentration-dependent reduction of cell proliferation in the LPS-treated HASMCs at 48 h and 72 h (Fig. 7C; P<0.01). However, miR-152 did not influence HASMC migration at 48 or 72 h (data not shown). These results also suggested that miR-152 has an anti-atherosclerotic effect by decreasing cell proliferation.

Discussion

Increasing evidence has revealed that the ERα protein has an atheroprotective effect and methylation in the ERα gene can cause atherosclerosis [17], [18]. However, the role of microRNAs in the regulation of ERα expression has not been extensively explored. The present study showed that miR-152 can down regulate DNMT1 which in turn inhibits methylation in the promoter of the ERα gene leading to higher ERα expression. Therefore, we identified that miR-152 has an anti-atherosclerotic effect via its effect on the increase of ERα expression. We also used LPS to induce hypermethylation of the ERα gene in HASMCs. Although statin failed to reverse the hypermethylation status in the ERα gene, the traditional Chinese medicine (SHXXT) partially recovered LPS-induced DNA hypermethylation. Furthermore, our animal studies confirmed the therapeutic effect of this Chinese medicine. Again, statin did not have any effect on increasing miR-152 but SHXXT could enhance miR-152 expression. Unfortunately, we did have available human samples to compare miR-152 concentrations between atherosclerotic and non-atherosclerotic tissues. Taken together, the present study not only identified a novel mechanism to regulate ERα expression but also provided data for the Chinese medicine SHXXT in the context of epigenetic therapy in the context of atherosclerosis and cardiovascular disease.

It is well known that estrogen has directly protective effect on the cardiovascular system [17], [34], [35]. Two types of ER (α and β subtypes) have been identified in VSMCs and endothelial cells. Several studies have shown that estrogen inhibits the proliferation and migration of VSMCs via ERα binding [17], [35], [36]. Furthermore, the anti-atherosclerotic effects of ERα also can be influenced by the methylation status in its promoter.
Our data provided more insight into how the ERα gene is regulated by epigenomic mechanisms and microRNA. Newman [37] first proposed that DNA hypomethylation is involved in the development of cardiovascular disease. Increased plasma homocysteine and S-adenosylhomocysteine (SAH) are associated with the inhibition of methyltransferases, which causes global DNA hypomethylation in VSMCs [38], [39], peripheral white blood cells [39] and atherosclerotic lesions [40]. More solid evidence from animal studies suggests that cellular proliferation is associated with global DNA hypomethylation and DNMT1 overexpression in atherosclerotic lesions [39]. Theoretically, over-expressed DNMT1 should cause DNA hypermethylation, but the paradoxical finding of increased global DNA hypomethylation and DNMT1 overexpression was reported in previous studies [39]. Therefore, there must be other mechanisms regulating DNA methylation, and in the present study we cannot rule out the involvement of these undiscovered mechanisms in ERα hypermethylation. Indeed, co-existence of global hypomethylation and hypermethylation in particular genes have been reported in the atherosclerosis [13].

Figure 5. Methylation of the ERα gene in HASMCs induced by LPS with or without SHXXT treatment. (A) Schematic diagram of the distribution of ERα exon 1 CpG islands in HASMCs (GenBank accession no. X03635.1 G1:31233) are shown. Black and white arrows indicated the PCR primer pair of methylation specific PCR (MSP) and bisulfite sequencing PCR (BSP), respectively. (B) Exon 1 of the ERα methylation status was analyzed by MSP at 48 h and 72 h. Electrophoresis showed methylation-specific PCR products from three conditions (Control, LPS treatment and LPS plus SHXXT treatment). UM: unmethylated; M: methylated ERα. (C) PCR primers specific to unmethylated and methylated bisulfite-modified DNA were used to amplify exon 1 of the ERα gene in LPS-induced HASMCs and SHXXT treatment. Amplified PCR products were cloned, and six individual clones were sequenced to determine the methylation status of the 24 CpGs within the amplified region. Open and filled circles indicate that the CpG site is unmethylated or methylated, respectively. Each row represents one clone. (D) Exon 1 of the ERα methylation status of the rat aortas were analyzed by MSP. UM: unmethylated; M: methylated ERα.

doi:10.1371/journal.pone.0030635.g005
Materials and Methods

HASMC culture and treatment

Human aortic smooth muscle cells (HASMCs, cryopreserved tertiary cultures; Cascade Biologics, Inc., OR, USA) were grown in culture flasks in smooth muscle cell growth media (Medium 231, Cascade Biologics, Inc., OR, USA). The smooth muscle cell growth medium consisted of fetal bovine serum (FBS, 5%), human epidermal growth factor (10 ng/ml), human basic fibroblast growth factor (3 ng/ml), insulin (10 mg/ml), penicillin (100 units/ml), streptomycin (100 pg/ml), and Fungizone (1.25 mg/ml). The cells were incubated at 37°C in a humidified 5% CO2 atmosphere. HASMCs were subcultured when the cells were about 70–80% confluence. Passages 4 to 9 were used for experiments. Lipopolysaccharide (LPS; 100 ng/mL) was used to induce an atherogenic change in HASMCs. Before LPS treatment, cells were grown under HASMC medium without FBS for 24 h. Cells were then incubated at 37°C for 24 h in the presence of LPS. SHXXT contains three components: 

- *Coptidis rhizome* (rhizomes of *Coptis chinesis* Franch; CR),
- *Scutellariae radix* (roots of *Scutellaria baicalensis* Georgi; SR), and
- *Rhei rhizome* (rhizomes of *Rheum officinale* Baill; RR).

SHXXT was prepared by as follows: powdered crude extracts of RR, SR and CR were weighed in a ratio of 2: 1: 1. Each extract was added to 10-fold volume of water and then boiled in different conditions individually. After finishing the extraction, the materials were filtered to yield three extraction solutions. Three hot solutions were combined and then condensed to 1/20 in volume of the total original water. The new formed condensed solution was spray-dried to get the final dry SHXXT. SHXXT was dissolved in deionized distilled water along with LPS for a 24 h incubation period. Simvastatin (1 μM; Sigma-Aldrich, MO, USA) was dissolved in ETOH and was subsequently diluted in saline. Both SHXXT and simvastatin were tested for the effect on DNA methylation of the *ERα* gene in the HASMCs.

Animal Preparation

Eight-week-old Sprague-Dawley male rats were divided to three groups (normal diet, high fat (HF) and HF plus SHXXT). SHXXT (30 mg/kg/day) or placebo (water) was orally fed using the ball-tipped feeding needle for 12 weeks. Rats were raised in a...
controlled environment at 20±2°C, with 40–70% relative humidity and an artificial 12-h light-dark cycle. All animal experiments were carried out in compliance with the “Guide for the Care and Use of Laboratory Animals” published by the National Academy of Sciences. The protocol was approved by the Kaohsiung Medical University Animal Research Committee (IACUC approval No.98018). After acclimatization for 1 week, eighteen rats were randomly divided into 3 groups. The composition of the HF diet was enriched with 30% fat. Access to food and water was unrestricted for either group. The body weight, food and water consumption of the animals were measured daily. Rats were killed at the end of 12th week. Their aortas were removed and immediately frozen in liquid nitrogen until assayed.

PCR of Alu repetitive elements

Methylation analysis of Alu repetitive elements was performed by the COBRA assay as described previously [41]. Methylation quantification was performed with a molecular Dynamics PhosphorImager.

Methylation specific PCR and sequencing

DNA was extracted from HASMCs and rat aortas by the DNA extraction kit (Qiagen, CA, USA). Next, bisulfite conversion was performed using the EZ DNA methylation Gold kit (Zymo research, CA, USA) according to the manufacturer’s instructions. Methylation specific PCR was then carried out to determine the methylation status of ERα. Bisulfite-modified DNA was used for PCR with primers specifically designed for methylated or unmethylated sequences (Table 1). The PCR conditions were as follows: 95°C for 5 min followed by 40 cycles of 95°C for 1 min, 56°C for 1 min and 72°C for 2 min, and then a final extension at 72°C for 7 min. PCR products were analyzed by electrophoresis in a 2.0% agarose gel containing ethidium bromide.

Bisulfite sequencing of HASMC DNA samples was performed as described previously [33]. The bisulfite-modified DNA was used to amplify a 208-bp product of ERα exon 1 gene with primer sets mentioned at Table 1. Two stage PCR were used to amplify a region with in the ERα CpG island (GenBank accession no. X03635.1 G1:31233). PCR products were cloned using pGEM-T Vector System according the manufacturer’s instructions (Promega). The sequenced DNA region for ERα was confirmed by using the automated sequencer (ABI automated DNA sequencer).

RNA interference

We used shRNA to perform RNA interference. The lentiviral plasmids expressing 21-mer shRNAs against DNMT1 (clone ID: TRCN0000021890) was obtained from the National RNAi Core Facility in the Academia Sinica (Taipei, Taiwan). HASMCs were transfected with the empty vector (pLKO.1 puro) or plasmids expressing shRNA (6 μg DNA per 10⁵ cells for 48 h) using Lipofectamine 2000 (Invitrogen, CA, USA).

MicroRNA transfection

A negative control miRNA (#17110), hsa-miR-152 precursor (Product ID: PM12269) and hsa-miR-152 inhibitor (Product ID: AM12269) were purchased from the Ambion Inc. (TX, USA).
Table 1. Primer sets.

| Species | Gene                  | Primer Sequence                                          |
|---------|-----------------------|----------------------------------------------------------|
| Human   | MSP for ERα          | Unmethylated-specific pair                               |
|         |                       | F: 5′-GTGTGGTATATTTGTGGAGGT-3′                           |
|         |                       | R: 5′-CTCAGCACCATATAACCTACAA-3′                          |
|         | Methylated-specific  | pair                                                     |
|         |                       | F: 5′-CTCCTTGTTAAATTTTGTGAGGT-3′                         |
|         |                       | R: 5′-CTCCCGCACGGTTATACGCTAA-3′                          |
|         | BSP for ERx          | First round pair                                          |
|         |                       | F: 5′-ATGTTTATTTGTTATGATAAAGAG-3′                        |
|         |                       | R: 5′-TATACCTAATACCTCCTCATAA-3′                          |
|         |                       | Second round pair                                         |
|         |                       | F: 5′-AGGTATTTTGGATTAGTGTAAGG-3′                         |
|         |                       | R: 5′-CTAACCCCTAAACTACAAAAAAA-3′                         |
|         | PCR for              | DNMT1                                                    |
|         |                       | F: 5′-GCACAAGACTGAACTGTTCA-3′                            |
|         |                       | R: 5′-GGCTTTTCACCTCAATCAA-3′                             |
|         | ERα                  | First round pair                                          |
|         |                       | F: 5′-GTACTGGCAAAAAGGCTGGTTGTT-3’                         |
|         |                       | R: 5′-GGTACCTGGGCAATCTTCTGACCACCT-3′                     |
|         | GAPDH                | F: 5′-GAAGGTTGAAAGTGCCAGTGC-3′                           |
|         |                       | R: 5′-GAAGATGTGATGGATTCT-3′                              |
| SD rat  | MSP for ERα          | Unmethylated-specific pair                               |
|         |                       | F: 5′-TGTTGTTGTTGTTGTTGTTG-3′                            |
|         |                       | R: 5′-TCAACAAATAACAACACAC-3′                             |
|         | Methylated-specific  | pair                                                     |
|         |                       | F: 5′-TTAAATTTCTCGAGGGTC-3′                              |
|         |                       | R: 5′-AAAAACGACCGACACCGAC-3′                             |
|         | PCR for              | DNMT1                                                    |
|         |                       | F: 5′-ACCTACACGCGCCGACAT-3′                              |
|         |                       | R: 5′-AGGTCTCTCCCTTCTCCTA-3′                             |
|         | ERα                  | F: 5′-GCTGCGCAAGTGTTACGAA-3′                             |
|         |                       | R: 5′-CTGTTTTATTGTATTAGATTTAAGGGAAT-3′                   |
|         | GAPDH                | F: 5′-CCCTTATGACCCTAATACCT-3′                            |
|         |                       | R: 5′-GGAAGGGCCATGCCAGTGC-3′                             |

HASMCs were transfected with miRNA precursor using Lipofectamine 2000.

RNA isolation, cDNA synthesis, and quantitative real-time PCR

Total RNA was isolated from HASMCs and rat aortas using Trizol reagent (Invitrogen, CA, USA). cDNA was synthesized by reverse transcription with 1 μg RNA using the SuperScript™ kit (Invitrogen, CA, USA). The 20 μl reverse transcription products were diluted to 100 μl and 2 to 3 μl was used for real-time PCR. Real-time PCR reactions were performed in a volume of 25 μl containing 140 ng specific primers (Table 1) and 12.5 μl SYBR green Master Mix (ABI, CA, USA) using the following condition: Initial denaturing: 95°C for 10 min, followed by 40 cycles of denaturing at 95°C for 30 s, annealing at 56°C for 40 s, and extension at 72°C for 30 s. The threshold cycle number (CT) value for the target gene (DNMT1 and ERα) was normalized against GAPDH and calculated as ΔCT = CTtarget − CTGAPDH. Expression levels of miRNA were quantified by employing the 2−ΔΔCT relative quantification method. Real-time PCR was performed for Has-miR-152 (UCAGUGCAUUCAGAGUUGG; Assay ID: 000430) using the specific TaqMan MiRNA Reverse Transcription kit (Applied Biosystems). All the reactions were amplified on a 7900 HT Fast Real Time PCR system (Applied Biosystems). Expression levels of miRNA were quantified employing the 2−ΔΔCT relative quantification method. The threshold cycle number (CT) value for miR-152 was normalized against RUG6 and calculated as ΔCT = CTmiR-152 − CRTUG6. Expression levels of miRNA were quantified by employing the 2−ΔΔCT relative quantification method.

Western blot for DNMT1 and ERα

HASMCs were homogenized in 100 μl of protein extraction reagent (Thermo Scientific, CA, USA) and protease inhibitor (Panomics, CA, USA). Protein concentration was determined by Pierce BCA Protein Assay Kit (Thermo Scientific, CA, USA). 20 μg of protein was loaded per lane and separated by NuPAGE Novex Bis-Tris 4–12% mini gel electrophoresis (Invitrogen, CA, USA) in the Novex Xcell-II apparatus for 120 min at 100 V, and transferred to Immobilon-PVDF transfer membranes (Millipore, MA, USA) for immunoblotting. Nonspecific binding was blocked with 5% nonfat milk for 1 h at the room temperature. Bands were visualized using specific antibodies for DNMT1 (Santa Cruz biotechnology, CA, USA) and ERα (Millipore, MA, USA) overnight at 4°C. Sequentially, the anti-mouse (for DNMT1) or anti-rabbit (for ERα) secondary antibodies were conjugated to horseradish peroxidase and enhanced chemiluminescence was determined using Fuji medical X-ray film (Fujifilm, Tokyo, Japan).

Cell proliferation and migration assay

To examine the effect of miR-152 on cell proliferation, HASMCs were transfected with the miR-152 precursor or inhibitor and then were incubated in microplates at 37°C with 5% CO₂ for 48 h and 72 h. After that 0.5 mg/ml of dimethyl-thiazol-diphenyltetrazoliumbromide (MTT; Sigma-Aldrich, MO, USA) was added into each well. Spectrophotometric readings were performed by X340 spectrophotometer at 595 nm (Bio-TEK Instruments, Inc., VT, USA). Migration assays were performed following a standard protocol-wound repair assay repair. The mechanical injury of confluent HASMCs and lesion repair assay were performed as described elsewhere [42]. HASMCs were cultured in 6-well plates at 2×10⁵ cells/well as confluent monolayers. The monolayers were incubated and wounded in a line across the well with a 200-μl standard pipette tip. The wounded monolayers were washed twice with phosphate-buffered saline (PBS) and incubated with serum-containing medium supplemented with LPS. The rate of wound closure was measured and photographed over 24 h.

Statistics

All values in the text and figures are expressed as mean ± SD. Statistical differences were evaluated by Student’s t-test. A p value<0.05 was considered statistically significant.

Author Contributions

Analyzed the data: Y-SW R-TL S-HHJ. Contributed reagents/materials/analysis tools: W-WC K-CC H-YC. Wrote the paper: Y-SW S-HHJ.
References

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, et al. (2009) Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: e21–181.

2. Abraham ST, Benscoter HA, Schweizer CM, Singer HA (1997) A role for Ca2+/calmumion-dependent protein kinase II in the mitogen-activated protein kinase signaling cascade of cultured rat aortic smooth muscle cells. Circulation Research 81: 573–584.

3. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135–1143.

4. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, et al. (2005) Platelet-dependent growth of calcium-sensitized human smooth muscle cell proliferation depends on basic FGF release and FGER-1 activation. Circulation Research 96: 172–179.

5. Libby P, Aikawa M (2002) Stabilization of atherosclerotic plaques: new mechanisms and medical targets. Nature Medicine 8: 1257–1262.

6. Pussenij PJ, Tsuzuki K, Jousilahti P, Havelun AM, Sundhav J, et al. (2007) Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 1433–1439.

7. Ross R (1999) Atherosclerosis—an inflammatory disease. The New England Journal of Medicine 340: 115–126.

8. Schwartz SM (1997) Smooth muscle migration in atherosclerosis and restenosis. The Journal of Clinical Investigation 100: 867–89.

9. Hiltunen MO, Yla-Herttuala S (2003) DNA methylation, smooth muscle cells, and arterogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 23: 1750–1753.

10. Lukkaenen MO, Mannenmaa S, Hiltunen MO, Aittomaki S, Sirehne K, et al. (1999) Local hypomethylation in atherosclerosis found in rabbit e-cod gene. Arteriosclerosis, Thrombosis, and Vascular Biology 19: 2171–2178.

11. Matouk CC, Marsden PA (2008) Epigenetic regulation of vascular endothelial gene expression. Circulation Research 102: 873–887.

12. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer.

13. Turunen MP, Aavik E, Yla-Herttuala S (2009) Epigenetics and atherosclerosis. Biochimica et Biophysica Acta 1790: 886–891.

14. Dong C, Yoon W, Goldschmidt-Clermont PJ (2002) DNA methylation and atherosclerosis. The Journal of Nutrition 132: 2400E–24008E.

15. Sharma P, Kumar J, Garg G, Kumar A, Patowary A, et al. (2008) Detection of altered global DNA methylation in coronary artery disease patients. DNA and Cell Biology 27: 357–363.

16. Lee ME, Wang H (1999) Homocysteine and homocystinemia. A novel link to vascular disease. Trends in Cardiovascular Medicine 9: 49–54.

17. Nakamura Y, Suzuki T, Miki Y, Tazawa C, Sznitka K, et al. (2004) Estrogen receptor-alpha expression decreases in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Molecular and Cellular Endocrinology 219: 17–26.

18. Post WS, Goldschmidt-Clermont PJ, Wilhide CG, Heldman AW, Susman MS, et al. (1998) Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovascular Research 43: 985–991.

19. Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Isa J, et al. (2000) Methylation of the estrogen receptor-alpha gene promoter is associated with aging and atherosclerosis in the cardiovascular system. Cardiovascular Research 43: 985–991.

20. Ruhani GM, Kauer K, Johns A (2002) Role of estrogen receptors in the vascular system. Vascular Pharmacology 30: 81–82.

21. Li E, Bestor TH, Jaenrich R (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915–926.

22. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dmmt3b are essential for de novo methylation and mammalian development. Cell 99: 247–257.

23. Huang J, Wang Y, Guo Y, Sun S (2010) Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 52: 60–70.

24. Bronco C, Huang N, Patel T (2010) MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocyties. Hepatology 51: 881–890.

25. Fabbi M, Gazzar R, Cimmino A, Liu Z, Zaneu N, et al. (2007) MicroRNA-29 family reverser aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104: 15805–15810.

26. Duurasma AM, Kedde M, Schirmer M, le Sage G, Agamai R (2008) miR-148 targets human DNMT3b protein coding region. RNA 14: 872–877.

27. Chen K, Wang YS, Ho CY, Chang WC, Liao YC, et al. (2011) OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MPP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. Faseb J.

28. Farmer JA (2000) Pleiotropic effects of statins. Curr Atheroscler Rep 2: 208–217.

29. Diederle L, Albani D, Sottocorni M, Donati MB, Bianchi M, et al. (2001) In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterosclerosis, Thrombosis, and Vascular Biology 21: 1327–1332.

30. Porter KE, Naik J, Turnier NA, Dickinson T, Thompson MM, et al. (2002) Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 36: 150–157.

31. Nishimura T, Vassar LT, Faul JL, Zhao G, Berry GJ, et al. (2003) Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108: 1640–1645.

32. Wang YS, Liu RT, Cheng HY, Yang SF, Chou WW, et al. (2011) Antiatherogenic effect of San-Huang-Xie-Xin-Tang, a traditional Chinese medicine, in cultured human aortic smooth muscle cells. Journal of Ethnopharmacology 133: 443–447.

33. Gitan RS, Shi H, Chen CM, Yan PS, Huang TH (2002) Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res 12: 158–164.

34. Christian RC, Liu PY, Harrington S, Ruan M, Miller VM, et al. (2006) Intram arterial estrogen receptor ERbeta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. The Journal of Clinical Endocrinology and Metabolism 91: 2713–2720.

35. Okubo T, Urabe M, Tsuchiya H, Iwasa K, Yokota K, et al. (2000) Effect of estrogen and progesterone on gene expression of growth regulatory molecules and proto-oncoenzyme in vascular smooth muscle cells. Endocrine Journal 47: 205–214.

36. Seeger H, Wallwinder D, Mueck AO (2001) Effect of medroxyprogesterone acetate and norethisterone on serum-stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells. Menopause 8: 5–9.

37. Newman PE (1999) Can reduced folate acid and vitamin B12 levels cause deficient DNA methylation producing mutations which initiate atherosclerosis? Medical Hypotheses 53: 421–424.

38. Yudrng J, Jianzhong Z, Ying H, Juan S, Jingue Z, et al. (2007) Homocysteine-mediated expression of SAHH, DNMTs, MBD2, and DNA hypomethylation potential pathogenic mechanism in VSMCs. DNA and Cell Biology 26: 603–611.

39. Hiltunen MO, Turunen MP, Hakkinen TP, Rosner T, Hedman J, Hildeman M, et al. (2002) DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vascular Medicine 7: 5–11.

40. Lund G, Andersson L, Lauria M, Lindholm M, Fraga MF, et al. (2004) DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. The Journal of Biological Chemistry 279: 29147–29154.

41. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, et al. (2004) A simple DNA methylation analysis. Curr Atheroscler Rep 2: 208–217.

42. Ashton AW, Yokota R, John G, Zhao S, Saudianci SO, et al. (1999) Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A2. The Journal of Biological Chemistry 274: 35562–35570.